Clinical Trial Update: A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update for MACI in patients aged 10 to 17 with symptomatic chondral or osteochondral defects of the knee, with recruitment curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Articular Cartilage Defect of the Knee
• Osteochondral Defect of the Knee
• Osteochondritis Dissecans of the Knee

Drugs mentioned

• MACI (matrix-induced autologous chondrocyte implantation)

Snippet

Sponsor: Vericel Corporation | Conditions: Chondral Defect, Osteochondritis Dissecans (OCD) | Phase 3 | Status: RECRUITING